FTSE 100 giant AstraZeneca is considering moving its listing to the US, marking a potential further blow to the health of London’s capital markets.
Pascal Soriot, the long-standing CEO of the pharmaceutical giant, has spoken in private about his preference to ditch the London Stock Exchange and has even considered moving the company's domicile, according to reports from The Times. Number of UK companies mulling moving their listing doubles in 12 months Sources familiar with the matter explained that he is exasperated with the UK's current operating environment, especially the regulation and restrictions around the approval of new medicines by the National Institute for Health and Care Excellence. Soriot would likely face res...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes